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Abstract
The purpose was to study the perinatal transmission of human papillomavirus DNA (HPV-DNA)
in 63 mother-newborn pairs, besides looking at the epidemiological factors involved in the viral
DNA transmission. The following sampling methods were used: (1) in the pregnant woman, when
was recruited, in cervix and clinical lesions of the vagina, vulva and perineal region; (2) in the
newborn, (a) buccal, axillary and inguinal regions; (b) nasopharyngeal aspirate, and (c) cord blood;
(3) in the children, buccal was repeated in the 4th week and 6th and 12th month of life. HPV-DNA
was identified using two methodologies: multiplex PCR (PGMY09 and MY11 primers) and nested-
PCR (genotypes 6/11, 16, 18, 31, 33, 42, 52 and 58). Perinatal transmission was considered when
concordance was found in type-specific HPV between mother/newborn or mother/child. HPV-
DNA genital was detected in 49 pregnant women submitted to delivery. Eleven newborns (22.4%,
n = 11/49) were HPV-DNA positive. In 8 cases (16.3%, n = 8/49) there was type specific HPV
concordance between mother/newborn samples. At the end of the first month of life three children
(6.1%, n = 3/49) became HPV-DNA positive, while two remained positive from birth. In 3 cases
(100%, n = 3/3) there was type specific HPV concordance between mother/newborn samples. In
the 6th month, a child (2%, n = 1/49) had become HPV-DNA positive between the 1st and 6th month
of life, and there was type specific HPV concordance of mother/newborn samples. All the HPV-
DNA positive children (22.4%, n = 11/49) at birth and at the end first month of life (6.1%, n = 3/
49) became HPV-DNA negative at the age of 6 months. The HPV-DNA positive child (2%, n = 1/
49) from 1st to the 6th month of life became HPV-DNA negative between the 6th and 12th month of
life and one child had anogenital warts. In the twelfth month all (100%, n = 49/49) the children
studied were HPV-DNA negative. A positive and significant correlation was observed between
perinatal transmission of HPV-DNA and the immunodepression of maternal variables (HIV, p =
0.007). Finally, the study suggests that perinatal transmission of HPV-DNA occurred in 24.5% (n =
12/49) of the cases studied.
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Introduction
Sexual transmission of human papillomaviruses (HPV) is
widely recognized as a cause of anogenital warts and cer-
vical cancer[1,2]. Today, the plurality of HPV is well-
established; more than 120 HPV types have been identi-
fied. Papillomaviruses are also suspected of playing a role
in a subset of oropharyngeal cancers, in squamous cell
skin cancers, and possibly also in esophageal cancers,
though the evidence is as yet less convincing than that for
cervical cancer[3].
HPV is a sexually transmitted disease common in adoles-
cents and adults[4]. It is becoming increasingly clear that
HPV-DNA can be acquired by non-sexual routes, and that
one of these would be mother-child transmission during
the perinatal period [5-8]. This vertical transmission of
HPV-DNA presumably may occur when the fetus passes
through the infected birth canal [9-12] or by ascending
infection, especially after premature rupture of the amni-
otic membranes [5-7]. Several authors referred to the pres-
ence of HPV in the amniotic liquid[13], in fetal
membranes[12], in nasopharyngeal aspirates of concepts
born by cesarean section[9,11], in cord blood[14] suggest-
ing that HPV-DNA contamination occurred before birth
(intrauterine) by transplacental route[14]. The implica-
tions of these observations have not yet been clearly estab-
lished. The non-concordance of type specific HPV
between mother and newborn appears to suggest the
existence of other transmission routes such as by phom-
ites (contaminated instruments), contact between the
child and people (interfamily, friends). In children, the
vertical transmission of HPV-DNA was related to juvenile
recurrent respiratory papillomatosis[15] and to genital
warts[16].
Therefore a prospective study was proposed in pregnant
women with molecular diagnosis of genital HPV-DNA, as
well as their newborns, in order to seek a better under-
standing of the risks of perinatal transmission of DNA
virus, and also to study a few maternal variables that
might be correlated with DNA virus transmission.
Materials and methods
Population studied
Between April 2005 and December 2008, a cross-sec-
tional, prospective study was performed on pregnant
women with a prior history of HPV infection, or who had
abnormal Papanicolaou smear or genital warts, due to the
high probability that they could have HPV infection. The
women were referred from the Obstetrical Service of the
University of Caxias do Sul and by the Basic Health Units
of the Single Health System of Caxias do Sul. This study
was performed with the approval of the Ethics Committee
in Research at the University of Caxias do Sul, and of the
Editorial and Scientific Board of the General Hospital of
Caxias do Sul, and did not present a conflict of interest.
The Letter of Free and Informed Consent and the epidemi-
ological evaluation tool were obtained from all the
women by individual interviews during the obstetrical
examinations. At the end of the study 63 pairs of mothers/
newborns were included in the research.
Epidemiological evaluation
The epidemiological study was performed taking the fol-
lowing variables into account: age, race, level of educa-
tion, smoking, marital status, marital stability, history of
immunodepression (HIV – acquired immunodeficiency
syndrome), type of HPV lesion (genital warts, LGSIL –
low-grade squamous intraepithelial lesions, HGSIL –
high-grade squamous intraepithelial lesions), site of HPV
lesion (cervical, vaginal, vulvar and perineal), numbers of
types of HPV-DNA in maternal genital (single, double and
multiple), gestational age at the time HPV infection was
diagnosed (weeks), time of labor (minutes), time of
amniotic membrane rupture (minutes), type of delivery
(cesarean section, vaginal and vaginal with forceps) and
HPV lesion at delivery (genital warts, LGSIL – low-grade
squamous intraepithelial lesions, HGSIL – high-grade
squamous intraepithelial lesions).
Sampling methods
Maternal
The maternal genital samples were obtained during preg-
nancy, at the first visit, when the pregnant woman was
recruited. The sample was obtained using a special brush
for cytopathological sampling of the cervix, which was
used for genital brushing in the following order: cervix
and possible clinical and subclinical lesions of the vagina,
vulva and perineal region. The brush was placed in a TE
solution (Tris HCl, pH 7.5 – 10 mM; EDTA, 1 mM), and
the material collected was kept frozen at -20°C, until the
desoxyribonucleic acid (DNA) was extracted.
Newborns
In newborns, in the first minutes of life, buccal, body,
nasopharyngeal aspirates and arterial blood were
obtained from the umbilical cord samples.
Buccal and body
The swabs were collected in the first minutes of life, using
the special brush for cytopathological sampling of the cer-
vix, with which brushing was performed in the following
order: buccal cavities, axillary and inguinal regions of the
newborn. The brush was placed in a TE solution (Tris HCl,
pH 7.5 – 10 mM; EDTA, 1 mM) and kept frozen at -20°C,
until DNA was extracted.
Collection with a brush from the buccal of the newborn
was repeated in the 4th week and 6th and 12th month of
life.Virology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
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Nasopharyngeal aspirates
The distal extremity of the tracheal aspiration catheter
(n°6 or 8, Sondas Descartáveis Mercosul® Linha Sondas
Descartáveis Mercosul®, Empresa CPL Medical's Produtos
Médicos LTDA), used to aspirate the upper airways
(nasopharyngeal) of the newborn immediately after birth,
was removed. The distal extremity of the catheter (about 4
cm long) was cut and placed in TE solution (Tris HCl, pH
7.5 – 10 mM; EDTA, 1 mM), keeping it frozen at -20°C,
until DNA was extracted.
Arterial cord blood
The sample was collected directly from one of the arteries
of the cord using a 3 ml disposable syringe (27/5 needle)
to obtain about 1 ml of fetal blood. The collection was
performed after clamping the cord and complete delivery
of the placenta and fetal membranes. The fetal blood was
placed in a KMA type tube with EDTA and frozen at -
20°C, until DNA was extracted.
DNA extraction
DNA was extracted in the blood and tissue samples using
the  Wizard Genomic DNA Purification Kit (Promega),
according to the manufacturer's specifications. In the
brush samples, DNA was extracted using 600 μl of NaOH
50 mM, stirred in a vortex for 5–10 seconds and later incu-
bated at 95°C for 5 minutes. The solution was then neu-
tralized with 60 μl of Tris HCl pH 8.0 and kept in a freezer
at -20°C, until it was submitted to the next stages.
After the DNA extraction methodology, the products were
submitted to two different PCR methods for HPV-DNA
identification and typing: PCR multiplex and type specific
nested multiplex PCR.
Amplification of the β-globin and HPV
The DNA samples obtained from the extraction method-
ology were amplified in multiplex PCR, and this was com-
posed by the PCO4 oligonucleotides (CAA CTT CAT CCA
CGT TCA CC) and GH20 (GAA GAG CCA AGG ACA GGT
AC), which amplified the segment of 268 base pairs (pb)
of the human β-globin gene, ensuring the qualification
and quantification of DNA for HPV analysis, and by the
PGM09 and PGMY11 oligonucleotides, which amplify a
segment of 450 pb of a preserved region of gene L1 of
Human Papillomavirus[17]. The thermocycler, model
PTC100 (MJResearch, Watertown, Mass) was used for
amplification; the parameters for denaturation, annealing
and lengthening of the ribbons were the following: 95°C
for 5 minutes, followed by 40 51°C cycles for 30 seconds,
55°C for 1 minute, 72°C for 1 minute and, finally, 72°C
for 5 minutes. Negative and positive controls were
included with all amplifications, and the negative control
was constituted by all elements except genomic DNA; and
the positive control was constituted by HPV-DNA type 16
previously typing (Diagnosis Molecular Laboratory of
University of Caxias do Sul). Four μg of the molecular
DNA of the DNA φ X 174RF HaeIII molecular weight
marker were used. The presence or absence of HPV-DNA
fragments and β-globin amplified from the oligonucle-
otides was analyzed in 1.5% agarose gel, in buffer TBE
0.5× with 0.3% ethidium bromide (0.1 mg/μL solution),
under ultraviolet light.
Viral typing
The HPV positive samples were submitted to a new type
of PCR-specific for viral type identification. For this pur-
pose the RFLP (Restriction Fragment Length Polymor-
phism) technique was used, according to the
methodology described by Bernard et al. (1994)[18]. The
amplified product was digested by the BamHl, Ddel,
Haelll, HinfI, PstI, RsaI and SauAIII enzymes and ana-
lyzed by vertical electrophoresis in 4% polyacrylamide gel
(20.3% acrylamide, 0.7 bisacrylamide, 0.07% ammo-
nium persulphate, TBE 1× TEMED 0.7 μL/mL – Gibco-
BRL). The pGEM (PROMEGA) was used as a molecular
weight marker. Later the samples in polyacrylamide gel
were stained with silver nitrate and the fragments
obtained compared to the prototypes described by Ber-
nard et al. (1994)[18].
Amplification by nested-PCR in region E6/E7 of the HPV
The nested multiplex PCR (NMPCR) assay combines
degenerate E6/E7 consensus primers and type-specific
primers for the detection and typing of HPV genotypes 6/
11, 16, 18, 31, 33, 35, 39, 42, 43, 44, 45, 51, 52, 56, 58,
59, 66 and 68. As to sensitivity and performance with clin-
ical samples, the novel NMPCR assay is a potentially use-
ful tool for HPV-DNA detection in epidemiologic and
clinical follow-up studies, especially when accurate HPV
typing and the detection of multiple HPV infections are
required.
The samples were amplified in the first PCR reaction using
the degenerated primers GP-E6-3F (GGG WGK KAC TGA
AAT CGG T), GP-E6-5B (CTG AGC TGT CAR NTA ATT
GCT CA) and GP-E6-6B (TCC TCT GAG TYG YCT AAT
TGC TC), W being A/T; K, G/T; R, A/G; Y, C/T and N, A/C/
G/T. These primers amplify a region of 630 pb of the E6/
E7 region of the 38 most common types of HPV. The
nested-PCR reaction is specific and was performed for
types 6/11, 16, 18, 31, 33, 42, 52 and 58, which represent
the viral types that are most prevalent in the region[19].
The primers used and the sizes of the amplified products
are listed in table 1. The entire procedures, both the first
reaction (PCR) and the second reaction (nested-PCR)
occurred according to Sotlar et al., 2004[20].
Perinatal transmission of HPV-DNA
In the study, perinatal transmission of HPV-DNA was con-
sidered when HPV type-specific agreement was observed
between the samples mother/newborn or mother/child.Virology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
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Statistical analysis
Statistical analyses were performed with the SPSS compu-
ter software package (version 12.0 for Windows). Fre-
quency tables were analyzed by using the chi-square test,
with Pearson and likelihood ratio tests for the significance
of differences between the categorical variables. The 95%
confidence interval (95% CI) was calculated where appro-
priate. Differences in the means of continuous variables
between the groups were analyzed by using nonparamet-
ric tests. In all analyses, probability values of < 0.05 were
regarded as significant.
Results
The genital HPV-DNA was detected in 49 women of the
63 who underwent delivery (mean age 23.9 ± 8 years; 14–
41 years). The distribution of the viral types identified in
the maternal genital samples are shown in table 2. Among
the HPV-DNA positive (HPV-DNA+) cases, 54.9%, 1.2%,
40.2% and 3.7% were considered high risk, possible high
risk, low risk and unclassified DNA, respectively[21]. The
HPV-DNA detected most frequently were types 6/11
(20.7%), 42 (15.9%), 16 (15.9%), 18 (11%), 58 (6.1%)
and 31, 35 and 52 (3.7% each). The numbers of types of
HPV-DNA identified in maternal genital were single, dou-
ble and multiple in 38.8%, 30.6% and 30.6% of the cases,
respectively.
When analyzing the samples obtained from buccal and
body scrapings, nasopharyngeal aspirate and arterial cord
blood obtained during the first minutes of life, it was
observed that 11 newborns (NB) (22.4%, n = 11/49) were
positive for the research of HPV-DNA (Table 3). Of the
HPV-DNA positive cases, 54.9%, 1.2%, 40.2% and 3.7%
were types considered a high carcinogenic risk, possible
high carcinogenic risk, low carcinogenic risk and non-clas-
sified DNA, respectively. Of this total of NB HPV-DNA+,
6 (12.2%, n = 6/49) were HPV-DNA+ in samples obtained
by scraping the buccal and body, 5 (10.2%, n = 5/49)
from the nasopharyngeal aspirate and 3 (6.1%, n = 3/49)
in arterial cord blood. Concordance of type specific HPV
was seen between the mother/NB in 16.3% (n = 8/49) of
the cases. There was type specific HPV concordance
Table 1: Sequences of type-specific nested PCR primers used in this study.
HPVgenotype Primer sequences Amplicon (pb)*
6/11 TGC AAG AAT GCA CTG ACC AC
TGC ATG TTG TCC AGC AGT GT
334
16 CAC AGT TAT GCA CAG AGC TGC
CAT ATA TTC ATG CAA TGT AGG TGT A
457
18 CAC TTC ACT GCA AGA CAT AGA
GTT GTG AAA TCG TCG TTT TTC A
332
31 GAA ATT GCA TGA ACT AAG CTC G
CAC ATA TAC CTT TGT TTG TCA A
263
33 ACT ATA CAC AAC ATT GAA CTA
GTT TTT ACA CGT CAC AGT GCA
398
42 CCC AAA GTA GTG GTC CCA GTT A
GAT CTT TCG TAG TGT CGC AGT G
277
52 TAA GGC TGC AGT GTG TGC AG
CTA ATA GTT ATT TCA CTT AAT GGT
229
58 GTA AAG TGT GCT TAC GAT TGC
GTT GTT ACA GGT TAC ACT TGT
274
* Base pairs.
Table 2: HPV types in maternal genital sample.
HPV-DNA
Type
n = 18
Carcinogenic risk Frequency
n = 82
%
6/11 LR 17 20.7
42 LR 13 15.9
16 HR 13 15.9
18 HR 9 11
58 HR 5 6.1
31 HR 3 3.7
35 HR 3 3.7
52 HR 3 3.7
51 HR 2 2.4
54 LR 2 2.4
59 HR 2 2.4
26 PHR 1 1.2
33 HR 1 1.2
34 HR 1 1.2
45 HR 1 1.2
68 HR 1 1.2
70 LR 1 1.2
73 HR 1 1.2
NC* - 3 3.7
The HPV types were identified by both multiplex PCR and nested 
multiplex PCR methods.*NC = HPV-DNA positive but could not be 
classified by type. LR – Low-risk HPV genotypes (HPV type 6, 11, 40, 
42, 43, 44, 54, 61, 70, 72, 81 and CP6108); HR – High-risk HPV 
genotypes (HPV type 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 
73 and 82); PHR – Probable high-risk HPV genotypes (HPV type 26, 
53 and 66)[21].V
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Table 3: Clinical and laboratory history of genital HPV infection during pregnancy and delivery and distribution of HPV types in maternal, newborns and children in 1st and 6th 
and 12th month of life samples.
Maternal epidemiology HPV type in samples
Pregnancy Delivery Maternal Newborn Children
Buccal
Case HPV lesion 
type
HPV lesion 
site
Type HPV lesion Genital Nasopharyngeal 
aspirates
Buccal and 
body
Cord blood 1st month of 
life
6th month of 
life
12th month of 
life
1 Warts VV V No 6/11
2 HGSIL C C No 16+6/11 6/11 6/11
3H G S I L C C Y e s 1 6 + 3 1
4 Warts VV V No 16+42+54 42
5L G S I L C C Y e s 1 8
6 Warts VV C No 6/11+16+31
7 Warts C+VV+VG V No 6/11+42 6/11 6/11
8H G S I L C C Y e s 5 2 6 / 1 1
9 LGSIL C V Yes 42+51+NC*
10 Warts VV+VG V No 6/11
11 LGSIL C V No 18 18 18
12 Warts VV V+F No NC*
13 LGSIL C C Yes 6/11+42
14 LGSIL C C Yes 16+42+58 59
15 Warts C+VV+VG V Yes 6/11+42
16 Warts VV+VG C No 6/11 6/11
17 HGSIL C C Yes 18+51
18 Warts VV+P C No 42+59
19 Warts VV V No 6/11
20 HGSIL C C No 42+35
21 Warts VV C Yes 52 52
22 Warts VV C Yes 34
23 Warts VV+VG V Yes 18
24 Warts VV V No 16+73
25 Warts VV+VG C No 68
26 Warts C V Yes 6/11+16 16
27 Warts C+VV+VG V No 16+58
28 Warts VV C Yes 6/11+33
29 LGSIL C V No 16
30 LGSIL C V Yes 52+42+58+54
31 LGSIL C C No 16
32 Warts VV C No 6/11V
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33 HGSIL C V Yes 18
34 Warts VV V Yes 11 11
35 Warts VV+VG C Yes 42 42
36 LGSIL C V Yes 16
37 HGSIL C C Yes 58 6/11+52 6/11
38 HGSIL C V No 6/11+18 6/11
39 HGSIL C C Yes 18+31
40 Warts VV V No 6/11
41 Warts VV C No 42+35+NC*
42 LGSIL C C Yes 42
43 LGSIL C C Yes 16+18+42
44 LGSIL C+VV+VG C Yes 18+26
45 Warts VV V Yes 6/11+58+59 6/11 6/11
46 Warts VV+VG C Yes 6
47 Warts VV V Yes 35
48 Warts VV V No 70
49 Warts VV+VG V No 6+45 6/11+52
50 LGSIL C V Yes -
51 Warts VV C No -
52 HGSIL** C C Yes -
53 Warts VV+VG C Yes -
54 HGSIL C V Yes -
55 LGSIL C V Yes -
56 HGSIL C V Yes -
57 HGSIL C V No -
58 HGSIL C C No -
59 HGSIL C C Yes -
60 LGSIL C V No -
61 HGSIL C V Yes -
62 LGSIL C C Yes -
63 HGSIL C V Yes -
The HPV types were identified by both multiplex PCR and nested multiplex PCR methods.*NC = HPV-DNA positive but could not be classified by type. **Child had anogenital warts (HPV type 6/
11) in the 12th month of life.
Delivery type = C – cesarean section; V- vaginal; and V+ F – vaginal with forceps.
HPV lesion site = C – cervical; VG – vaginal; VV – vulva; P- perineal.
HPV lesion type = Warts – genital warts; LGSIL – low-grade squamous intraepithelial lesions; HGSIL – high-grade squamous intraepithelial lesions.
Table 3: Clinical and laboratory history of genital HPV infection during pregnancy and delivery and distribution of HPV types in maternal, newborns and children in 1st and 6th 
and 12th month of life samples. (Continued)Virology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
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between the maternal genital sample and the samples of
the buccal and body scraping, nasopharyngeal aspirate
and arterial cord blood of the NB, of 83.3% (n = 5/6),
60% (n = 3/5) and 100% (n = 3/3), respectively. Of the
HPV-DNA+ cases, 66.7% and 33.3% were types consid-
ered a low and high carcinogenic risk, respectively. The
types of HPV-DNA detected were: 6/11 (53.3%); 42, 18,
52 (13.3% each); and 59 (6.7%). One NB (n = 1/11,
9.1%) had HPV-DNA+ for two different types of virus.
Studying the buccal samples of infant, obtained at the end
of the first month of life, it was observed that five children
(10.2%, n = 5/49) had HPV-DNA+ (Table 3). Three of
these children (6.1%, n = 3/49) became HPV-DNA+ dur-
ing the first month of life, while two were positive since
birth. Concordance of the type specific HPV was observed
between mother/NB in 100% (n = 3/3) of the new cases.
Of the HPV-DNA+ cases, 66.7% and 33.3% were types
considered low and high carcinogenic risk, respectively.
The types of HPV-DNA detected were: 6/11 (53.3%), 16
and 52 (13.3% each). One NB (20%, n = 1/5) had HPV-
DNA+ for two different types of virus. Nine (81.8%, n = 9/
11) of the eleven children that were HPV-DNA+ at birth
became HPV-DNA negative at the end of the first month
of life.
Studying the buccal samples from infant, obtained in the
6th month of life, it was observed that one child (2%, n =
1/49) had become HPV-DNA+ between the 1st and 6th
month of life (Table 3). There was agreement of the type
specific HPV between the mother/NB (HPV type 6/11).
All the children who were HPV-DNA+ (22.4%, n = 11/49)
at birth and at the end first month of life (6.1%, n = 3/49)
became HPV-DNA negative at the age of 6 months.
Studying the buccal samples of infant, obtained in the
12th month of life, all the children (30.6%, n = 15/49)
who were HPV-DNA+ from birth to the 6th month of life
became HPV-DNA negative between the 6th  and 12th
month of life (Table 3).
One (1.6%, n = 1/63) child had anogenital warts in the
12th month of life. The type of HPV-DNA detected was 6/
11. In this case, in epidemiological maternal history, it
was observed that the pregnant joined the research for
high-grade squamous intraepithelial lesions, with nega-
tive result for HPV-DNA. This child was born by cesarian
section without early rupture of membranes and by
restricted fetal growth. The mother showed normal results
in colposcopic and Papanicolaou smear evaluates in the
2nd, 5th, 8th and 12th months postpartum. The buccal sam-
ples of the child remained HPV-DNA negative during the
12 months of life.
Analyzing the demographic and behavioral factors (Table
4) a positive and significant correlation was found
between the presence of HPV-DNA in the NB or child and
maternal history of immunodepression (HIV, p = 0.007).
The statistical analysis did not show any significant asso-
ciation between the presence of HPV-DNA in the NB or
child and the other variables studied (Tables 4 and 5).
HPV detection and typing methods
Evaluating the HPV-DNA detection and typing methods it
was observed that the multiplex PCR methodology iden-
tified HPV-DNA in 41 pregnant (83.7%, n = 41/49). In 31
pregnant women (75.6%, n = 31/41) only a single type of
HPV-DNA was identified, and in 10 pregnant women
(24.4%, n = 10/41) two or more types of HPV-DNA. The
nested multiplex PCR method (although used for identi-
fication and typing of 9 types of HPV-DNA represented as
the most prevalent in the city of Caxias do Sul) identified
HPV-DNA in 43 pregnant women (87.8%, n = 43/49). In
28 pregnant women (65.1%, n = 28/43) only one type of
HPV-DNA was identified and in 15 pregnant women
(34.9%, n = 15/43) two or more types of HPV-DNA.
Together the multiplex PCR and nested multiplex PCR
methods identified HPV-DNA in 49 pregnant women
(100%, n = 49/49). In 19 pregnant women (38.8%, n =
19/49) only one type of HPV-DNA was identified and in
30 pregnant women (61.2%, n = 30/49) two or more
types of HPV.
The multiplex PCR method identified HPV-DNA only in
two newborns or children (13.3%, n = 2/15), while the
nested multiplex PCR method identified it in 13 new-
borns or children (86.7%, n = 13/15).
Discussion
HPV infection is considered a sexually transmitted disease
common in sexually active young women, with an esti-
mated prevalence between 20% and 46%[4,22,23]. In
pregnant women the prevalence of HPV infection fluctu-
ates around 25%[24,25]. Prior studies suggested that the
HPV infection could be transmitted during the perinatal
period [26-28]. This is a study between mother and new-
born, whose type specific HPV agreement between the
pair characterized the vertical transmission of the virus.
The presence of HPV-DNA in the maternal genital area
may be considered a risk factor for fetal exposure to the
virus. In this study, among the types of HPV identified in
the maternal genital samples, 54.9% were considered a
high carcinogenic risk. HPV infection has been identified
in 1% to 20%[27,29] of babies newly born to pregnant
women who do not show any evidence of cervical HPV
infection, and in 5% to 72%[30,31] in newborns of
women with a diagnosis of the viral infection during preg-
nancy. Gajewska et al. (2006)[25], detected HPV genital
(prevalence of HPV types 6/11 – 18%; HPV type 16 –
13%) in 26% (n = 10/39) of the pregnant women andVirology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
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observed a high percentage (70%) of HPV transmission
from mother to neonate. Rice et al. (2000)[32] identified
HPV-DNA type 16 in samples of the oral cavity of children
aged 3 to 11 years, and related the results to possible peri-
natal and interfamilial transmission. On concluding,
these authors suggested that in future vaccination pro-
grams and studies of the different transmission routes of
HPV should be introduced.
Sedlacek et al. (1989)[33] showed the presence of HPV-
DNA in nasopharyngeal aspirates of newborns delivered
by vaginal route to mothers with HPV-DNA in uterine cer-
vix cells. Authors have described the presence of HPV-
DNA in amniotic liquid[13], in cord blood[14], in fetuses
with malformations[7] and in specimens from first tri-
mester spontaneous abortions[34]. The presence of HPV-
DNA in newborns no implies the presence of viral infec-
tions but may demonstrate the mechanism by which the
virus can be transmitted during the perinatal period.
In the study discussed here, on analyzing the samples of
buccal and body scrapings, nasopharyngeal aspirate and
Table 4: HPV status of the newborn and children and maternal factors.
Maternal variable Newborn and children HPV-DNA
Positive
(n = 12)
Negative
(n = 37)
Age (years)
≤ 19 6 (50%) 17 (45.9%)
≥ 20 to ≤ 29 3 (25%) 12 (32.4%)
≥ 30 to ≤ 39 3( 2 5 % )6 ( 1 6 . 2 % )
≥ 40 to ≤ 49 --2 ( 5 . 4 % )
Mean for newborn HPV-DNA positive group (25.3 ± 8.1 years) - - - -
Mean for newborn HPV-DNA negative group (23.6 ± 8.2 years) - - - -
Race
White 10 (83.3%) 34 (91.9%)
Non-white 2 (16.7%) 3 (8.1%)
Level of education
Illiterate ----
Elementary (complete or incomplete) 7 (58.3%) 21 (56.8%)
High school (complete or incomplete) 4 (33.3%) 16 (43.2%)
College (complete or incomplete) 1 (8.4%) - -
Smoking
No 7 (58.3%) 27 (73%)
< 10 cigarettes per day 1 (8.3%) 5 (13.5%)
≥ 10 cigarettes per day 4 (33.3%) 5 (13.5%)
Marital status
Married 1 (8.3%) 10 (27%)
Single 3( 2 5 % )8 ( 2 1 . 6 % )
Cohabiting 7 (58.4%) 18 (48.6%)
Divorced, separated 1 (8.3%) 1 (2.7%)
Marital stability (years)
≤ 2 9 (75%) 25 (67.6%)
≥ 3 to ≤ 5 2 (16.7%) 8 (21.6%)
≥ 6 1 (8.3%) 4 (10.8%)
Mean for newborn HPV-DNA positive group (2.9 ± 4.6 years) - - - -
Mean for newborn HPV-DNA negative group (2.9 ± 4.7 years) - - - -
History of Immunodepression (HIV)*
No 10 (83.3%) 37 (100%)
Yes 2( 1 6 . 7 % )- -
Data are reported as number and percentage (in parentheses) of newborn and children infection positive or negative for human papillomavirus. *P 
< 0.007 indicates a statistically significant difference between the positive and negative groups by Pearson's chi-square test (HIV – acquired 
immunodeficiency syndrome).Virology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
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Table 5: HPV status of the newborn and children and delivery factors.
Maternal variable Newborn and children HPV-DNA
Positive
(n = 12)
Negative
(n = 37)
Type of HPV lesion
Genital warts 7 (58.3%) 21 (56.8%)
LGSIL1 2 (16.7%) 10 (27%)
HGSIL2 3( 2 5 % )6 ( 1 6 . 2 % )
Site of HPV lesion
Uterine cervix 5 (41.7%) 16 (43.2%)
Vulva 4 (33.3%) 12 (32.4%)
Vulva + vagina 2( 1 6 . 7 % )5( 1 3 . 5 % )
Vulva + perineal region --1 ( 2 . 7 % )
Uterine cervix + vulva + vagina 1 (8.3%) 3 (8.2%)
Type of HPV Infection
Single 6 (50%) 13 (35.2%)
Double 1( 8 . 3 % ) 1 4 ( 3 7 . 8 % )
Multiple 5 (41.7%) 10 (27%)
Type of delivery
Vaginal 5 (41.7%) 18 (48.6%)
Vaginal + forceps --1 ( 2 . 7 % )
Cesarean section 7 (58.3%) 18 (48.6%)
Mean of the gestational age at delivery in the newborn HPV-DNA positive group (39.3 ± 0.9 weeks)
Mean of the gestational age at delivery in the newborn HPV-DNA negative group (39.3 ± 2.4 weeks)
Gestational age at the time HPV infection was diagnosed (weeks)
≥ 4 to ≤ 12 4 (33.3%) 15 (40.5%)
≥ 13 to ≤ 28 4( 3 3 . 3 % )8( 2 1 . 6 % )
≥ 29 to ≤ 42 2( 1 6 . 7 % )6( 1 6 . 3 % )
Prior to pregnancy 2( 1 6 . 7 % )8( 2 1 . 6 % )
Mean in the newborn HPV-DNA positive group (14.6 ± 13.6 weeks)
Mean in the newborn HPV-DNA negative group (13.3 ± 12 weeks)
Time of RUPREME3(min)
≤ 360 12 (100%) 34 (91.9%)
≥ 361 to ≤ 720 --1 ( 2 . 7 % )
≥ 721 --2 ( 5 . 4 % )
Mean of newborn HPV-DNA positive group (39 ± 56 minutes) - - - -
Mean of newborn HPV-DNA negative group (103 ± 240 minutes) - - - -
Time of labor (min)
≤ 240 6 (50%) 22 (61.1%)
≥ 241 to ≤ 360 3( 2 5 % )9( 2 5 % )
≥ 361 3( 2 5 % )6 ( 1 3 . 9 % )
Mean of newborn HPV-DNA positive group (213 ± 225 minutes) - - - -
Mean of newborn HPV-DNA negative group (194 ± 196 minutes) - - - -
HPV lesion at delivery
Yes 7 (58.3%) 19 (51.4%)
No 5 (41.7%) 18 (48.6%)
Data are reported as number and percentage (in parentheses) of newborn and children infection positive or negative for human papillomavirus. *P 
< 0.043 indicates a statistically significant difference between the positive and negative groups by Pearson's chi-square test. 1Low-grade squamous 
intraepithelial lesions. 2High-grade squamous intraepithelial lesions. 3RUPREME = rupture of amniotic membrane.Virology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
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arterial cord blood obtained in the first minutes of life, it
was observed that 11 NB (22.4%, n = 11/49) were positive
for HPV-DNA research, 54.9% of which were considered
of high carcinogenic risk. Concordance of the type specific
HPV was also observed between mother/NB in 16.3% (n
= 8/49) of the pairs, characterizing the possibility of trans-
mission of HPV-DNA intrauterine or during the delivery.
The different types of HPV identified among the mother/
newborn pairs (6.1%, n = 3/49) can be explained by con-
tamination of the sample or of the PCR technique
(unlikely, due to the methodologies used to prevent con-
tamination of the PCR methods), or by infection from
multiple types of HPV, or by viral subtypes and/or vari-
ants.
This study also showed the efficacy of the multiple sample
methodology in the newborn, eliminating false negative
results for HPV-DNA research. The results obtained cor-
roborate Mazzatenta et al. (1996)[35] who in their study
concluded that a simple sample can have a satisfactory
result in clinical screening, even if it is not a reliable
method to evaluate the risk of vertical transmission of
HPV.
The behavior of the presence of HPV-DNA in newborns
can be understood by prospective follow up studies and
obtaining repeated samples. The present study suggests
that the presence of the HPV-DNA in children of mothers
HPV-DNA+ in genital sample fluctuates during the first six
months of life. Out of the 11 NB who presented HPV-
DNA+, only two children continued HPV-DNA+ in sam-
ples obtained from the buccal after the first month of life.
Three children (6.1%, n = 3/49) became HPV-DNA+ dur-
ing the first month of life. When children were evaluated
in the 6th month of life, all of them became HPV-DNA
negative, even if a new case of a HPV-DNA+ appeared for
buccal samples. This "regression" of the presence of HPV-
DNA in buccal could be explained by the silent neutrali-
zation of antibodies that have migrated transplacentally,
from the mother to the fetus, and that are functionally
active in neonatal circulation, or contamination by mater-
nal infected cells in NB delivered vaginally and that tend
to disappear during the first months of life. This dimin-
ished number of HPV-DNA+ children could be explained
by the results shown by Kawana et al. (2003)[36]. These
authors found type 6 anti-HPV antibodies in the maternal
blood and in the blood of newborns of infected mothers.
The authors suggested that their finding should be better
defined and that their study could be considered an
important step to understand the prevention of vertical
transmission of HPV. Kaye et al. (1996)[37], Cason et al.
(1995)[6], Pakarian et al. (1994)[29] Tenti et al.
(1999)[38] demonstrated that the HPV-DNA in children
examined at three different moments, tends to become
negative between birth and the 6th month of life. Puranen
et al. (1997)[9] reported the persistence of HPV through-
out the first 3 years of life, although the persistence of oral
HPV-DNA was not detected in other follow up stud-
ies[27,38].
The new cases of children who were HPV-DNA+ in the
buccal at the end of the first (n = 3) and sixth (n = 1)
month of life, could be explained by the agreement
(100%) of the type specific HPV between mother/NB.
This agreement of HPV-DNA suggests that these children
may have been exposed to HPV-DNA: during the intrau-
terine period or during the delivery and that the HPV-
DNA was only identified after birth[39]; or during the
post-birth period, when caring for the child (interfamilial
transmission – mother/child)[40].
One (n = 1/63, 1.6%) child had anogenital warts (HPV-
DNA type 6/11) in the 12th month of life. The incidence
of anogenital warts in children has increased dramatically
since 1990 [41-43]. Before 1990, only 136 cases of ano-
genital warts had been reported in children, yet between
1990 and 1994, at least 326 additional cases were
described [42,43]. The increase in incidence of anogenital
warts in children is thought to parallel the increase in inci-
dence of anogenital warts in the adult population[43].
Adams (2001)[44] classification scale for evaluation med-
ical findings of suspected sexual abuse lists anogenital
warts/condyloma in a child younger than 2 years of age as
a nonspecific finding for sexual abuse-perinatal transmis-
sion must be considered. Vertical transmission can occur
through the bloodstream prior to birth, or at the time of
birth, as the infant passes through the infected birth canal.
Delivery via cesarean section does not eliminate the pos-
sibility of vertical transmission of HPV; there are reports
of congenital condyloma after cesarean section without
premature rupture of membranes[43]. HPV can be trans-
mitted no sexually from direct contact with caretaker con-
taminate with genital HPV or common warts [41,43]. For
example, caretakers with genital warts who touch or
scratch their genitals and then without washing their
hands change a baby's diaper or assist a child with toilet-
ing/bathing may transmit the virus to the child's genitals.
A caretaker with common warts of the hands could trans-
mit HPV in the same manner. HPV transmission via con-
tact with contaminated objects or surfaces is possible [43].
Sexual abuse must never be eliminated when considering
possible modes of transmission for anogenital HPV in
younger children[42].
In three cases no concordance of the type specific HPV
between mother/NB were observed. The different types of
HPV-DNA identified among the mother/NB pairs can be
explained by infection from multiple types of HPV, or by
viral subtypes and/or variants.
The positive and significant correlation between presence
HPV-DNA+ in the newborn or child and the maternal var-Virology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
Page 11 of 12
(page number not for citation purposes)
iables "history of immunodepression" (HIV, p = 0.007)
may be related to the special characteristics of the preg-
nancy, especially to the changes in the hormonal and
immunological balance prevailing during this period,
which could favor vertical transmission of the virus. In
adults, the risk factors for HPV-DNA transmission have
been well established. The chances of perinatal transmis-
sion and the differences in the known rates of HPV-DNA
transmission, are probably more closely related to the
viral load of the infected cells than to the risk factors estab-
lished for HPV infection[38].
Although the nested multiplex PCR methodology is used
to identify only 9 types of HPV represented as the most
prevalent in the city of Caxias do Sul, it had an excellent
performance to identify maternal HPV-DNA, and also
considerably increased the total number of pregnant
women with infections caused by multiple viruses. In the
samples of newborns, the nested multiplex PCR showed
its great sensitivity and specificity to identify HPV. The use
of that method was also essential to evaluate the agree-
ment of type specific HPV-DNA between the maternal/
newborn samples, thus defining the perinatal transmis-
sion rates.
The perinatal transmission of HPV-DNA was suggested
when concordance of the type specific HPV was observed
between mother/NB and mother/child: eight newborns,
three children at the end first month of life and a child in
the 6th month of life. In conclusion, perinatal transmis-
sion of HPV-DNA was suggested in 24.5% (n = 12/49) of
the newborns of mothers with genital warts or intraepi-
thelial lesions of the uterine cervix. Thus, a different man-
agement can be adopted for each of the different stages
(pre-gestational, gestation, delivery, and the first months
post partum), both from the diagnostic and therapeutic
perspective. Clinical observation of the mother and the
newborn must be maintained, and preventive educational
measures established for forms of HPV-DNA transmis-
sion, besides effective strategies for specific immuniza-
tion.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RLR participated in the design of the study, sampling
methods and performed the statistical analysis. RLR made
substantial contributions to conception and design,
acquisition of data and analysis and interpretation of
data. EPS has been involved in drafting the manuscript or
revising it critically for important intellectual content.
EPS and JM conceived of the study, and participated in its
design and coordination. RLR, EPS, JM, KPL and EZ par-
ticipated in the sequence alignment and drafted the man-
uscript. JM, KPL and EZ carried out the molecular studies.
RLR, EPS, JM, KPL and EZ have given final approval of the
version to be published.
References
1. Schiffman MH, Bauer HM, Hoover RN, Glass AG, Cadell DM, Rush
BB, Scott DR, Sherman ME, Kurman RJ, Wacholder S, Stanton CK,
Manos MM: Epidemiologic Evidence Showing That Human
Papillomavirus Infection Causes Most Cervical Intraepithe-
lial Neoplasia.  J Natl Cancer Inst 1993, 85:958-964.
2. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L,
Zahurak ML, Daniel RW, Viglione M, Symer DE, Shah KV, Sidransky
D: Evidence for a Causal Association Between Human Papil-
lomavirus and a Subset of Head and Neck Cancers.  J Natl Can-
cer Inst 2000, 92:709-720.
3. zur Hausen H: Papillomaviruses in human cancers.  Proc Assoc
Am Physicians 1999, 111:581-587.
4. Munoz N: Human papillomavirus and cancer: the epidemio-
logical evidence.  J Clin Virol 2000, 19:1-5.
5. Rice PS, Cason J, Best JM, Banatvala JE: High risk genital papillo-
mavirus infections are spread vertically.  Rev Med Virol 1999,
9:15-21.
6. Cason J, Kaye JN, Jewers RJ, Kambo PK, Bible JM, Kell B, Shergill B,
Pakarian F, Raju KS, Best JM: Perinatal infection and persistence
of human papillomavirus types 16 and 18 in infants.  J Med Virol
1995, 47:209-218.
7. Eppel W, Worda C, Frigo P, Ulm M, Kucera E, Czerwenka K:
Human papillomavirus in the cervix and placenta.  Obstet
Gynecol 2000, 96:337-341.
8. Minkoff H, Chervenak FA: Elective primary cesarean delivery.  N
Engl J Med 2003, 348:946-950.
9. Puranen MH, Yliskoski MH, Saarikoski SV, Syrjanen KJ, Syrjanen SM:
Exposure of an infant to cervical human papillomavirus
infection of the mother is common.  Am J Obstet Gynecol 1997,
176:1039-1045.
10. Xu S, Liu L, Lu S, Ren S: Clinical observation on vertical trans-
mission of human papillomavirus.  Chin Med Sci J 1998, 13:29-31.
11. Favre M, Majewski S, De Jesus N, Malejczyk M, Orth G, Jablonska S:
A possible vertical transmission of human papillomavirus
genotypes associated with epidermodysplasia verruciformis.
J Invest Dermatol 1998, 111:333-336.
12. Wang X, Zhu Q, Rao H: Maternal-fetal transmission of human
papillomavirus.  Chin Med J (Engl) 1998, 111:726-727.
13. Armbruster-Moraes E, Ioshimoto L, Leao E, Zugaib M: Presence of
human papillomavirus DNA in amniotic fluids of pregnant
women with cervical lesions.  Gynecol Oncol 1994, 54:152-158.
14. Tseng CJ, Lin CY, Wang RL, Chen LJ, Chang YL, Hsieh TT, Pao CC:
Possible transplacental transmission of human papillomavi-
ruses.  Am J Obstet Gynecol 1992, 166:35-40.
15. Silverberg MJ, Thorsen P, Lindeberg H, Grant LA, Shah KV: Condy-
loma in Pregnancy Is Strongly Predictive of Juvenile-Onset
Recurrent Respiratory Papillomatosis.  Obstet Gynecol 2003,
101:645-652.
16. Obalek S, Jablonska S, Favre M, Walczak L, Orth G: Condylomata
acuminata in children: frequent association with human pap-
illomaviruses responsible for cutaneous warts.  J Am Acad Der-
matol 1990, 23:205-213.
17. Gravitt PE, Peyton CL, Alessi TQ, Wheeler CM, Coutlee F, Hild-
esheim A, Schiffman MH, Scott DR, Apple RJ: Improved Amplifica-
tion of Genital Human Papillomaviruses.  J Clin Microbiol 2000,
38:357-361.
18. Bernard H, Chan S, Manos M, Ong C, Villa L, Delius H, Peyton C,
Bauer H, Wheeler C: Identification and assessment of known
and novel human papillomaviruses by polymerase chain
reaction amplification, restriction fragment length polymor-
phisms, nucleotide sequence, and phylogenetic algorithms.  J
Infect Dis 1994, 170:1077-1085.
19. Rombaldi RL, Serafini EP, Villa LL, Vanni AC, Barea F, Frassini R,
Xavier M, Paesi S: Infection with human papillomaviruses of
sexual partners of women having cervical intraepithelial
neoplasia.  Braz J Med Biol Res 2006, 39:177-187.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Virology Journal 2009, 6:83 http://www.virologyj.com/content/6/1/83
Page 12 of 12
(page number not for citation purposes)
20. Sotlar K, Diemer D, Dethleffs A, Hack Y, Stubner A, Vollmer N, Men-
ton S, Menton M, Dietz K, Wallwiener D, Kandolf R, Bultmann B:
Detection and Typing of Human Papillomavirus by E6
Nested Multiplex PCR.  J Clin Microbiol 2004, 42:3176-3184.
21. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah
KV, Snijders PJF, Meijer CJLM, the International Agency for Research
on Cancer Multicenter Cervical Cancer Study Group: Epidemio-
logic Classification of Human Papillomavirus Types Associ-
ated with Cervical Cancer.  N Engl J Med 2003, 348:518-527.
22. Dunne EF, Unger ER, Sternberg M, McQuillan G, Swan DC, Patel SS,
Markowitz LE: Prevalence of HPV Infection Among Females in
the United States.  JAMA 2007, 297:813-819.
23. Auvinen E, Zilliacus R, Malm C, Karkkulainen T, Fingerroos R, Paavo-
nen J: Repeated human papillomavirus DNA findings among
female university students.  Int J STD AIDS 2007, 18:839-841.
24. Hernandez-Giron C, Smith JS, Lorincz A, Arreola Chaidez E, Lazcano
E, Hernandez-Avila M, Salmeron J: [The prevalence of high-risk
HPV infection in pregnant women from Morelos, Mexico].
Salud Publica Mex 2005, 47:423-429.
25. Gajewska M, Wielgos M, Kaminski P, Marianowski P, Malejczyk M,
Majewski S, Marianowski L: The occurrence of genital types of
human papillomavirus in normal pregnancy and in pregnant
renal transplant recipients.  Neuro Endocrinol Lett 2006,
27:529-534.
26. Smith EM, Ritchie JM, Yankowitz J, Swarnavel S, Wang D, Haugen TH,
Turek LP: Human papillomavirus prevalence and types in
newborns and parents: concordance and modes of transmis-
sion.  Sex Transm Dis 2004, 31:57-62.
27. Watts DH, Koutsky LA, Holmes KK, Goldman D, Kuypers J, Kiviat
NB, Galloway DA: Low risk of perinatal transmission of human
papillomavirus: results from a prospective cohort study.  Am
J Obstet Gynecol 1998, 178:365-373.
28. Puranen M, Yliskoski M, Saarikoski S, Syrjanen K, Syrjanen S: Vertical
transmission of human papillomavirus from infected moth-
ers to their newborn babies and persistence of the virus in
childhood.  Am J Obstet Gynecol 1996, 174:694-699.
29. Pakarian F, Kaye J, Cason J, Kell B, Jewers R, Derias NW, Raju KS,
Best JM: Cancer associated human papillomaviruses: perina-
tal transmission and persistence.  Br J Obstet Gynaecol 1994,
101:514-517.
30. Fredericks BD, Balkin A, Daniel HW, Schonrock J, Ward B, Frazer IH:
Transmission of human papillomaviruses from mother to
child.  Aust N Z J Obstet Gynaecol 1993, 33:30-32.
31. Smith EM, Johnson SR, Jiang D, Zaleski S, Lynch CF, Brundage S,
Anderson RD, Turek LP: The association between pregnancy
and human papilloma virus prevalence.  Cancer Detect Prev
1991, 15:397-402.
32. Rice PS, Mant C, Cason J, Bible JM, Muir P, Kell B, Best JM: High
prevalence of human papillomavirus type 16 infection
among children.  J Med Virol 2000, 61:70-75.
33. Sedlacek T, Lindheim S, Eder C, Hasty L, Woodland M, Ludomirsky
A, Rando R: Mechanism for human papillomavirus transmis-
sion at birth.  Am J Obstet Gynecol 1989, 161:55-59.
34. Hermonat PL, Han L, Wendel PJ, Quirk JG, Stern S, Lowery CL, Rech-
tin TM: Human papillomavirus is more prevalent in first tri-
mester spontaneously aborted products of conception
compared to elective specimens.  Virus Genes 1997, 14:13-17.
35. Mazzatenta C, Fimiani M, Rubegni P, Andreassi L, Buffi P, Messina C:
Vertical transmission of human papillomavirus in cytologi-
cally normal women.  Genitourin Med 1996, 72:445-446.
36. Kawana K, Yasugi T, Yoshikawa H, Kawana Y, Matsumoto K, Naka-
gawa S, Onda T, Kikuchi A, Fujii T, Kanda T, Taketani Y: Evidence
for the presence of neutralizing antibodies against human
papillomavirus type 6 in infants born to mothers with condy-
loma acuminata.  Am J Perinatol 2003, 20:11-16.
37. Kaye JN, Starkey WG, Kell B, Biswas C, Raju KS, Best JM, Cason J:
Human papillomavirus type 16 in infants: use of DNA
sequence analyses to determine the source of infection.  J Gen
Virol 1996, 77(Pt 6):1139-1143.
38. Tenti P, Zappatore R, Migliora P, Spinillo A, Belloni C, Carnevali L:
Perinatal transmission of human papillomavirus from gravi-
das with latent infections.  Obstet Gynecol 1999, 93:475-479.
39. Leptak C, Ramon y Cajal S, Kulke R, Horwitz BH, Riese DJ 2nd, Dotto
GP, DiMaio D: Tumorigenic transformation of murine kerati-
nocytes by the E5 genes of bovine papillomavirus type 1 and
human papillomavirus type 16.  J Virol 1991, 65:7078-7083.
40. Cripe TP, Haugen TH, Turk JP, Tabatabai F, Schmid PG 3rd, Durst M,
Gissmann L, Roman A, Turek LP: Transcriptional regulation of
the human papillomavirus-16 E6-E7 promoter by a keratino-
cyte-dependent enhancer, and by viral E2 trans-activator
and repressor gene products: implications for cervical car-
cinogenesis.  Embo J 1987, 6:3745-3753.
41. Cohen BA: Warts and children: Can they be separated?  JAAPA.
1997, 12(12):63-68.
42. Siegfried E, Rasnick-Conley J, Cook S, Leonardi C, Monteleone J:
Human Papillomavirus Screening in Pediatric Victims of
Sexual Abuse.  Pediatrics 1998, 101:43-47.
43. Syrjanen S, Puranen M: Human papillomavirus infections in chil-
dren: the potential role of maternal transmission.  Crit Rev Oral
Biol Med 2000, 11:259-274.
44. Adams JA: Evolution of a Classification Scale: Medical Evalua-
tion of Suspected Child Sexual Abuse.  Child Maltreat 2001,
6:31-36.